Optibrinz T Eye Drop contains Brinzolamide 1% w/v + Timolol 0.5% w/v, a clinically proven anti-glaucoma combination formulated to lower elevated intraocular pressure in patients suffering from open-angle glaucoma and ocular hypertension. Its balanced formulation ensures effective and sustained pressure reduction.
The eye drop works through a dual mechanism of action, where Brinzolamide reduces aqueous humor production by inhibiting carbonic anhydrase, while Timolol further decreases aqueous formation via beta-blockade, providing enhanced IOP control and optic nerve protection.
From a commercial standpoint, Optibrinz T Eye Drop is a high-prescription ophthalmic product, widely used in eye hospitals, glaucoma clinics, and specialty ophthalmology practices, ensuring consistent demand, repeat prescriptions, and stable turnover.
Including Optibrinz T Eye Drop in your portfolio strengthens the anti-glaucoma combination segment, delivering long-term business growth, strong doctor confidence, and competitive advantage for PCD pharma franchise partners.